Materialise(MTLS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, consolidated revenue grew by 6.8% year-on-year, reaching EUR 70.2 million [13] - Gross profit margin increased to EUR 40.8 million, representing 58.1% of revenue [13] - Adjusted EBIT was EUR 4 million, with a margin of 5.7% [13] - Net profit for the quarter was EUR 6.2 million, more than double the previous year's EUR 2.9 million [25] Business Line Data and Key Metrics Changes - Materialise Medical revenue grew by over 16% in Q4, accounting for 53% of consolidated revenue [15] - Software revenue remained stable at around EUR 11 million, with recurring revenue growing by 4% year-on-year [21] - Manufacturing revenue declined by 2% year-on-year to EUR 22.2 million, with a negative adjusted EBITDA of -EUR 2.2 million [22] Market Data and Key Metrics Changes - Materialise Medical segment represented 50% of total annual revenue for 2025, while manufacturing and software accounted for 35% and 15%, respectively [15] - The company faced unfavorable foreign exchange effects, primarily from a weaker US dollar, impacting top-line growth [15] Company Strategy and Development Direction - The company aims to continue investing in Materialise Medical and Software segments while maintaining cost control in Manufacturing [29] - A dual listing on Euronext Brussels was established to access a broader investor audience and enhance operational flexibility [5] - The focus will be on high-growth sectors like aerospace and defense, with expectations of continued growth in these areas [36] Management's Comments on Operating Environment and Future Outlook - Management expects macroeconomic headwinds to persist in the industrial market segments throughout 2026 [29] - The Materialise Medical segment is anticipated to grow at a double-digit pace, while the Software segment will complete its transition to a cloud-based model [29] - Manufacturing results are expected to be flat to down due to a weaker industrial climate, particularly in Europe [35] Other Important Information - The company announced a share buyback program of up to EUR 30 million, which started on January 26, 2026 [5] - Cash reserves at year-end increased to EUR 134 million, with a net cash position of EUR 17.8 million [25] Q&A Session Summary Question: Is manufacturing expected to be down year-over-year? - Management confirmed that manufacturing is expected to be flat to down due to the weaker industrial climate [35] Question: What percentage of manufacturing is for prototyping applications? - The company has not disclosed this percentage but acknowledged that prototyping remains a significant part of the business [37] Question: Can costs be reduced to achieve EBITDA breakeven in manufacturing? - Management indicated that they will continue to focus on cost optimization in manufacturing and overhead across the company [38] Question: Was there a one-time cost in Q4's operating expenses? - Management clarified that Q4 operating expenses included non-recurring costs related to the Euronext listing, which should be excluded from future projections [39]